You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 157 No. 21, 24 NOVEMBER 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  REVIEW ARTICLE
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (47)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Update on Rifampin Drug Interactions, III

Valerie A. Strayhorn, PharmD; Anne M. Baciewicz, PharmD; Timothy H. Self, PharmD

Arch Intern Med. 1997;157(21):2453-2458.


Abstract

Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes. Examples of well-documented, clinically significant interactions include warfarin, oral contraceptives, cyclosporine, glucocorticoids, ketoconazole, theophylline, quinidine, digitoxin, and verapamil. Recent reports have demonstrated clinically relevant interactions with protease inhibitors, zidovudine, delavirdine, itraconazole, nifedipine, midazolam or triazolam, nortriptyline, and doxycycline. To avoid reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Enhanced knowledge of known interactions will continue to develop, including research on induction of specific cytochrome P-450 isoenzymes. New rifampin interactions will be discovered with further investigations.

Arch Intern Med. 1997;157:2453-2458



Author Affiliations

From the Department of Clinical Pharmacy, University of Tennessee, Memphis (Drs Strayhorn and Self), and the Department of Pharmacy Services, University Hospitals of Cleveland, Cleveland, Ohio (Dr Baciewicz).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

SIMULTANEOUS MEASUREMENT OF 23 ISOFORMS FROM THE HUMAN CYTOCHROME P450 FAMILIES 1 TO 3 BY QUANTITATIVE REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION
Girault et al.
Drug Metab. Dispos. 2005;33:1803-1810.
ABSTRACT | FULL TEXT  

Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test
Lemahieu et al.
Am. J. Physiol. Gastrointest. Liver Physiol. 2003;285:G470-G482.
ABSTRACT | FULL TEXT  

Disseminated Mycotic Infection Caused by Colletotrichum acutatum in a Kemp's Ridley Sea Turtle (Lepidochelys kempi)
Manire et al.
J. Clin. Microbiol. 2002;40:4273-4280.
ABSTRACT | FULL TEXT  

Rifampin and Rifabutin Drug Interactions: An Update
Finch et al.
Arch Intern Med 2002;162:985-992.
ABSTRACT | FULL TEXT  

Antibiotic Therapy for Musculoskeletal Infections
Mader et al.
JBJS 2001;83:1878-1890.
FULL TEXT  

Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males
Polk et al.
Antimicrob. Agents Chemother. 2001;45:502-508.
ABSTRACT | FULL TEXT  

The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm et al.
Am. J. Pathol. 2000;157:1575-1580.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.